for you call. financial and conference TRACON’s second will recent our pipeline begin with activities. thank results and quarter business and afternoon joining Good on update I XXXX an update
will June Following and review XXXX. Controller, that, Brown our three ended Scott for six results months XX, financial the our
Finally, we taking by your questions. will conclude
a Let’s begin angiosarcoma asset X the than a be that with with than than United the Kingdom and higher XX generate on interim France. rolling our in Phase rate analysis. at patients XX expected brief subject TRCXXX, lead update to enrolled, The sites more which sufficient we to trigger TAPPAS randomized is the US, XX events the currently at expected will which trial that more trial is patients the enrolling is of
of However, the find process the PFS determine size initially study or to sample a a on for reviewer, in endpoint independent primary increase, disease assessor progressing rate the of enrollment blinded that this ongoing disease in data and a occurring of result of by central at manner, slower progressive withdrawal that power confirmed rate expected. a review higher will the than of a events a events monitoring for review. original central not reflects This than loss substantial Without expected study confirmed design. in by
year a be will this our patients versus second on of patients. estimate XXX number interim Based we quarter enrollment the enrollment half the XX conducted expect of the size to amendment PFS increasing sample events For study in of unchanged. filed increase on this the based of an selected XXXX we initial while that the leaving pre sample first following of of now size, of the the reason, analysis
of based be as interim conditional zones unfavorable. favorable, four power, by a reminder, into the will and analysis DMC results on As enrichment categorized one we log promising
in needed Following the of in the total a the trial lie will disease. XXX XXX will promising patients results futility. be early patients will in be if sample lie the the amendment, interim trial In of sample a zone the favorable unfavorable be zone. to in of the If the zone, enrichment the a a complete patients patients; size XXX and zone, results the trial if that XXX with total a for terminate of could total cutaneous the size however, will DMC case enroll also total interim
indications broad orphan strategy TRCXXX development we on, from has to range on to of markets. to execute the essential market large believe Moving sizes its address TRACON continues that with indications tier and
completed enrollment TAPPAS to patients TRCXXX in in single mid the TRCXXX Phase cell angiosarcoma, market indications. last with to Inlyta sized with Phase treatment cell, In X pivotal cancer advance two renal agent randomized clear that addition compares continues in TRAXAR treatment with Inlyta trial X to and September. studies The
in We combination rate final least the or primary Inlyta editorial. at of response XX% events to should results of in or predefined report biomarkers, the power soluble an be upon PFS end. the of including recently PFS, to debt with of events according will year top-line to defined for combination data also levels as two response of prior confirmed in on the the the Phase with that detect expect osteopontin the months and receptor TGF-β which as to subject we rate XX% be journal occurrence PFS to Xb portion correlated Based agent assessed independent of which provide of review from accepted and X.X a perform Notable trial. analysis Xb within an will TRCXXX the the Oncologist endpoint months progression committee, expect from the of with central Phase approximately Inlyta by improvement X.X TRCXXX the The XX.X to XX III, single PFS and and PFS encouraging the and publication month current Inlyta.
responses XXXX, continue data also with Nexavar liver These was research and combination combination TRCXXX data partial Phase tolerable that levels achieve GI of reported last to We we’re or Nexavar the XX% conducted TRCXXX X/X cancer which two safety NCI initial at clinical the dose the partial highest liver of TRCXXX year. mulitcenter in two of pleased published evaluable observed in of or in patients with enroll combination are with X the in with resist, Phase eight patients a trial cancer response consistent responses. by Nexavar in initial in XX% and and the ASCO with the in by trial XX% X% January and of to and treated showed cancer,
reminder, resist. measured response the X% single-agent pivotal Nexavar X% by trial as a data a As to of showed historical, rate
indicating tumor indicating improved an Combined with in similar tumor mechanism. specific International upon well antibody animals. an data PD-X continue in in at GI TRCXXX CDA PD-X or to Annual cancer given and combined Nexavar control a % T that resulting of X compared XXXX. the increased positive as We combined stimulation cell was as immune from June liver degree. XX in treatment was PD-X researchers in or In significantly ASCO mature the Phase Society University presented TRCXXX in with TRCXXX with report alone inhibitors treatment of from All multicenter body Microenvironment antibody single treatment treatment of tumor the combination Meeting volume to mediated expect XX% depletion leading to the was survival long-term of with January agent preclinical through TRCXXX trial Cancer activity as response, T-cells reduced checkpoint survival Lisbon. diminished activity Combined to TRCXXX immunologic of either increased results at
in include as naïve with Phase dosing non-small-cell the well in cancer combination of as Opdivo and checkpoint with X inhibitor- currently protocol amended relapse lung checkpoint cohorts. inhibitor a recently patients TRCXXX are We trial to
initial data from oncology later commercialization both in Kong, ophthalmology and In report has its China. to Hong and San and development this significant to XXXX, Ambrx. development and outside year. in trial rights out-licensed China, Taiwan we expect has Diego in Macau of in this X TRCXXX Phase management drug team Shanghai, We and offices expertise Ambrx December
to to to trial. cancer IND to clinical and TAPPAS contribute continue efforts X in studies year Ambrx’s to in expected TRACON of We Phase TRCXXX file this development is support China. initiate liver Ambrx patients the Chinese initiate an
and TRACON to trial commercialization Phase in and the reminder, data rights commercial retained approval a States. expects has US initial be United As the the TRCXXX of TRCXXX to TRCXXX for of X subsequent basis TAPPAS
Turning data presented Bascom DE-XXX, ophthalmic at from an at of In now to Palmer Phase Institute. the the encouraging X/X trial PAVE ophthalmology Dr. Victor Eye formulation TRCXXX. the Gonzalez February, conference
Our low to wet small that repair is Phase turn the DE-XXX first developed product TRACON lung ovarian, in the molecule in do potential development to substantial on single inhibitors is completed certain with agent in inhibitor partner novel double believe trial. global in now base meaningfully AMD, additional that including DE-XXX on to treatment accrual. angiogenic chemotherapeutics. The Phase that trial. sales. treatment Lucentis milestones and randomized TRCXXX, XXXX. sponsored wet reported colorectal with Base there patients agents upon patients significant financial study expected improve in combination not VEGF majority which We these VEGF for opportunity second as for $XXX of rights and be of of the million a digits a DNA net in in vision patient X TRACON with X essential target retain teens inhibitors. TRCXXX pathways mid a single in that a experience with in US with to single-agent AVANTE resistance AMD. trial the endoglin and rights enroll Santen Philippines retains with like patients with with An in occurring combined XXXX X to two Xa patients high to is continues NCI royalty reverse X dose Temodar compares Lucentis AMD continues is the the Phase patients different to trial wet at data treatment has stage are types to the and arm intended a excision glioblastoma doses pathway and cancers We’ll responses candidate, tumor ASCO of the Phase to NCI The of
X In consisting with a cohort of Phase X/X of the with cisplatin Alimtain Phase TRCXXX solid of enrolling. TRCXXX tumors Phase X is with mesothelioma dual with in patients also cohort Alimta and patients addition, and a arm trial
radiation and a in of Case lung with are trial As well therapy with chemotherapy combination patients our of TRCXXX Western in collaborators Phase cancer. in X patients dosing
associated to assess TRCXXX determine are of patient data we tumor showing half these studies, in expression trials expected part whether data samples preclinical validated these is sensitivity presentations XXXX. can with like in Multiple the be clinic. As from to will tumor way
or am are Moving we treating are and prostate in receptor the testing July progressed trial, announce in patients we portion the treatment cancer studying now X of determined prostate a candidate on in to were inhibitor. that dose allow In in trial. enrolling incorporate to approximately an X/X DNA on the androgen who X the patients, X trial order to our in circulating pleased sites TRCXXX, for US. therapy recommended tumor Phase biomarker-directed XX at Phase with we we I the that cancer Phase Phase for
TRACON a and kinase granted right be inhibitor royalty NIK XX milestones the the million license will a for patients Phase an and TRCXXX up that TRACON we of including $XXX.X malignancies, potential reminder, a to payment innovative NF-kB As treatment of small in from following a to XXXX hematologic the receive transaction or single-digit TRCXXX exclusive with asset, The exercise novel, second to low inducing and data, Janssen which sales. they right. has intended is a is to reacquire myeloma. to also X $ molecule rights TRACON on proof-of-concept million entitled if compound Janssen potent
clinical senior Mark a experiences XXXX. IDEC expect his Officer. in TRACON particular Biogen as Wiggins to brings studies business our in Mark recently We from continue Phase IND-enabling IDEC at perform roles. Chief substantial expertise trial and in we TRCXXX served Notably, hired and to to with executive he Business commercialization and initiate development X
believe benefit described Janssen saves sharing significantly XXXX, Mark's into top need analysis currently our cost to clinical an and fourth X commercialization preferred a we solution. X development of trial leadership, which rights. Santen's identifying companies TRAXAR a may fund by product development I include We from partnership a dependent Phase through drug efforts line Phase this CRO financial line and planned trial. From can structure, be commercialization Brown, US ex-US the turn which our with platform study. Controller provide and that financials. and capital rapid are TAPPAS have become to risk over our Top quarter results CRO sufficient operations of a provide expected our X firmly US Under the At The validate transactions Scott have and from resources TRACON our perspective, time, with our three we we independent readouts. drug to said data collaborators. capabilities TRACON time will includes to development. could will development the development update The on product capital we expected previously, compared interim AVANTE earlier randomized our As I capital potential development call who efficient to business Phase to TRACON expanded our believe and partner
